Analysis of ATM protein expression in 908 stage II/III CRC patients from the VICTOR randomised controlled trial comparing the effect of adjuvant rofecoxib against placebo in reducing recurrence in patients who had undergone tumor resection showed that low ATM expression compared to normal mucosa was independently associated with poor disease-free survival (HR = 1.67, 95% CI 1.11–2.50, p = 0.015) (41). This evidence concerns the gene ATM and colorectal carcinoma.